GPN Vaccines Ltd
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
GPN Vaccines Ltd - overview
Established
2017
Location
Adelaide, TAS, Australia
Primary Industry
Biotechnology
About
Founded in 2017 and based in Adelaide, Australia, GPN Vaccines Ltd. is a biotechnology company developing a next-generation vaccine to combat Streptococcus pneumoniae, a leading cause of pneumonia, sepsis, and other illnesses. In June 2024, GPN Vaccines Ltd. raised USD 18 million in Series B funding co-led by investors Forepont Capital and Kern Capital, with participation from individual investors.
As of June 2024, the company is led by CEO Tim Hirst. GPN Vaccines' primary product is Gamma-PN, a whole-cell vaccine designed to offer protection against all S. pneumoniae serotypes, bacteremia, and meningitis, as well as otitis media (middle ear infections). The company also offers Pfizer's Prevnar-20 to target a limited number of serotypes.
The company's streamlined manufacturing process, leveraging advanced microbial fermentation and irradiation techniques, promises cost-effectiveness and scalability. As of 2023, GPN Vaccines is conducting clinical trials to evaluate the safety, tolerability, and immunogenicity of Gamma-PNTM in comparison to Prevnar 13 and Pneumovax 23. The company will use the funding to bring innovative vaccines to market and improve global health outcomes.
Current Investors
Kern Capital, Forepont Capital Partners, Shearwater Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development, Pharmaceuticals
Website
www.gpnvaccines.com/
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.